Caspase Inhibition Modulates Monocyte-Derived Macrophage Polarization in Damaged Tissues

Int J Mol Sci. 2023 Feb 19;24(4):4151. doi: 10.3390/ijms24044151.

Abstract

Circulating monocytes are recruited in damaged tissues to generate macrophages that modulate disease progression. Colony-stimulating factor-1 (CSF-1) promotes the generation of monocyte-derived macrophages, which involves caspase activation. Here, we demonstrate that activated caspase-3 and caspase-7 are located to the vicinity of the mitochondria in CSF1-treated human monocytes. Active caspase-7 cleaves p47PHOX at aspartate 34, which promotes the formation of the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase complex NOX2 and the production of cytosolic superoxide anions. Monocyte response to CSF-1 is altered in patients with a chronic granulomatous disease, which are constitutively defective in NOX2. Both caspase-7 down-regulation and radical oxygen species scavenging decrease the migration of CSF-1-induced macrophages. Inhibition or deletion of caspases prevents the development of lung fibrosis in mice exposed to bleomycin. Altogether, a non-conventional pathway that involves caspases and activates NOX2 is involved in CSF1-driven monocyte differentiation and could be therapeutically targeted to modulate macrophage polarization in damaged tissues.

Keywords: CSF1; NOX2; caspase; differentiation; lung fibrosis; macrophage.

MeSH terms

  • Animals
  • Caspase 7 / metabolism
  • Caspases* / metabolism
  • Humans
  • Macrophage Colony-Stimulating Factor* / metabolism
  • Macrophages / metabolism
  • Mice
  • Monocytes / metabolism
  • NADPH Oxidases / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • Macrophage Colony-Stimulating Factor
  • Caspase 7
  • Caspases
  • Reactive Oxygen Species
  • NADPH Oxidases

Grants and funding

Our work was supported by the Commissariat Général à l’Investissement and the Agence Nationale de la Recherche (LabEx LipSTIC, IHU-B Molecular Medicine in Oncology), the Ligue Nationale Contre le Cancer (équipe labelisée) and the Institut National du Cancer (SIRIC SOCRATE). Peter Vandenabeele received a Methusalem grant (BOF09/01M00709 and BOF16/MET_V/007).